Table 1.
Patient characteristics. Study enrolled 180 consecutive and eligible hepatocellular carcinoma patients. The p values are from the Wilcoxon/Fisher’s exact test.
| Characteristics/ Surgical Intervention |
Liver Resection | Liver Transplantation | p-Value | |
|---|---|---|---|---|
| Age, years (n) | 64 (16, 79) (120) | 57 (30, 68) (60) | <0.0001 | |
| Milan criteria (n within, %) | 45/119 (37.8%) | 33/51 (64.7%) | 0.0015 | |
| Edmondson Steiner grade (n, %) | 0.044 | |||
| I/II | 10/116 (8.6%) | 10/44 (22.7%) | ||
| II/III | 96/116 (82.8%) | 31/44 (70.5%) | ||
| III/IV | 10/116 (8.6%) | 3/44 (6.8%) | ||
| Tumor size (cm ± SD, n) | 7.0 ± 3.6 (118) | 4.0 ± 1.7 (53) | <0.0001 | |
| Nodules (n, %) | 0.0009 | |||
| 1 | 100/120 (83.3%) | 35/57 (61.4%) | ||
| 2 | 14/120 (11.7%) | 11/57 (19.3%) | ||
| 3 | 3/120 (2.5%) | 8/57 (14.0%) | ||
| 4+ | 3/120 (2.5%) | 3/57 (3.7%) | ||
| Nodules (n ± SD, n) | 1.2 ± 0.6 (120) | 1.8 ± 1.4 (57) | 0.0007 | |
| INR (range, n) | 1.1 (1.0, 1.2) (41) | 1.4 (1.2, 1.5) (54) | <0.0001 | |
| Pre-operative HBV (n, %) | 49/119 (41.2%) | 42/60 (70.0%) | 0.0003 | |
| Pre-operative HCV (n, %) | 47/119 (39.5%) | 15/60 (25.0%) | 0.067 | |
| Pre-operative HDV (n, %) | 7/119 (5.9%) | 26/60 (43.3%) | <0.0001 | |
| Pre-operative cirrhosis (n, %) | 80/119 (67.2%) | 59/60 (98.3%) | <0.0001 | |
| CTP score (n, %) | 0 | 5/120 (29.2%) | 0/59 (0.0%) | <0.0001 |
| A | 78/120 (65.0%) | 17/59 (28.8%) | ||
| B | 7/120 (5.8%) | 42/59 (71.2%) | ||
| MELD score (median, range) | 8 (6–11) | 13 (7–28) | <0.0001 | |
| Surgery type (n, %) | <0.0001 | |||
| Liver resection | 108/120 (90.0%) | 0/60 (0.0%) | ||
| Liver resection + RFA/sorafenib/TACE/PCT | 12/120 (10.0%) | 0/60 (0.0%) | ||
| Liver transplantation | 0/120 (0.0%) | 59/60 (98.3%) | ||
| Liver transplantation + RFA/TACE | 0/120 (0.0%) | 1/60 (1.7%) | ||
CTP, Child–Turcotte–Pugh; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; INR, international normalized ratio; RFA, radiofrequency ablation.